Prescribing by numbers : drugs and the definition of disease
著者
書誌事項
Prescribing by numbers : drugs and the definition of disease
Johns Hopkins University Press, c2007
- : hbk
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references (p. [241]-308) and index
内容説明・目次
内容説明
The second half of the twentieth century witnessed the emergence of a new model of chronic disease-diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop-that arose in concert with a set of safe, effective, and highly marketable prescription drugs. In Prescribing by Numbers, physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. Prescribing by Numbers highlights the complex historical role of pharmaceuticals in the transformation of disease categories. Greene narrates the expanding definition of the three principal cardiovascular risk factors-hypertension, diabetes, and high cholesterol-each intersecting with the career of a particular pharmaceutical agent.
Drawing on documents from corporate archives and contemporary pharmaceutical marketing literature in concert with the clinical literature and the records of researchers, clinicians, and public health advocates, Greene produces a fascinating account of the expansion of the pharmaceutical treatment of chronic disease over the past fifty years. While acknowledging the influence of pharmaceutical marketing on physicians, Greene avoids demonizing drug companies. Rather, his provocative and comprehensive analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical analysis can help to address the problems inherent in the program of pharmaceutical prevention.
目次
Preface
Acknowledgments
Introduction: The Pharmacopoeia of Risk Reduction
Part One: Diuril and Hypertension, 1957-1977
1. Releasing the Flood Waters: The Development and Promotion of Diuril
2. Shrinking the Symptom, Growing the Disease: Hypertension after Diuril
Part Two: Orinase and Diabetes, 1960-1980
3. Finding the Hidden Diabetic: Orinase Creates a New Market
4. Risk and the Symptom: The Trials of Orinase
Part Three: Mevacor and Cholesterol, 1970-2000
5. The Fall and Rise of a Risk Factor: Cholesterol and Its Remedies
6. Know Your Number: Cholesterol and the Threshold of Pathology
Conclusion: The Therapeutic Transition
Notes
Index
「Nielsen BookData」 より